In clinical trials, vitamin E has shown a positive effect on improving biochemical indicators (such as alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels) and hepatic pathological features in patients with NAFLD (53–57). This evidence concerns the gene GPT and metabolic dysfunction-associated steatotic liver disease.